OCT 06, 2016 6:00 AM PDT

Heterogeneity and Resistance Mechanisms in Advanced Prostate Cancer

Speaker
  • Director of Clinical Research of Urology Associates (UA)
    Biography
      Raoul S. Concepcion, M.D., F.A.C.S., is the current Director of Clinical Research of Urology Associates (UA), a fully integrated 32 physician Urology group in Nashville Tennessee. He is Immediate Past President of the Large Urology Group Practice Association (LUGPA), a non for profit entity representing the interests of over 2500 Urologists in the U.S. affiliated with large single specialty Urology groups. Dr. Concepcion was a General Surgery and Urology Resident at Vanderbilt University School of Medicine from 1984 - 1989. He served as Chief Urology Resident from 1989 - 1990 and was also a research fellow in the Light Laboratories at Vanderbilt. He has been in practice with Urology Associates since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction. He has an academic appointment at The Vanderbilt School of Medicine as Associate Clinical Professor, Department of Urology. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeon and the Nashville Surgical Society. He also serves as a board member for ZERO, a non for profit organization for prostate cancer research based in Washington D.C., and the Nashville chapter of Gilda's Club. Dr. Concepcion serves as a speaker or consultant for many pharmaceutical and laboratory companies in the advanced prostate cancer and biomarker world, including Amgen, Dendreon, Janssen, Medivation, Astellas, Bayer, Algeta, Takeda, Mitomics, Myriad, Metamark Genetics and MDxHealth. He is also the co-founder of CUSP, a urology specific clinical trials organization, and Medical Advisor to the Chan Soon-Shiong Institute for Advanced Health and NantHealth.

    Abstract

    Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castration resistant prostate cancer (mCRPC).  Despite these advances, however, the disease remains fatal and is the second leading cause of cancer specific death in men over the age of 50 years old in the United States.  This presentation will focus on the heterogeneity of prostate cancer, review the role of the androgen receptor (AR) in disease progression and discuss molecular mechanisms and mutations that result in treatment resistance.
     


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources